Summary
This edition of Clinical Evidence examines personalised strategies in Implantable Cardioverter Defibrillator (ICD) therapy, spotlighting the latest technologies and comparing their respective strengths and limitations in minimising complications and inappropriate shocks1. As implant rates rise, we also unpack the factors influencing longevity in subcutaneous systems (S-ICDs), as reported by Ziacchi et al.2 in their review of emerging real-world data.
In our third article, the INGEVITYTM+ lead is shown to achieve high implantation success, stable electrical performance, and low complication rates in left bundle branch area pacing (LBBAP).3 Finally, we turn to insertable cardiac monitors (ICMs), where advances in detection algorithms are helping to reduce false positives in the LUX-DxTM II+.4
Key Takeaways
Device selection in ICD therapy: Monkhouse et al.1 advise moving beyond implantation criteria to prioritise individualised device selection.
Battery performance in modern S-ICDs: Ziacchi et al.2 conclude real-world device longevity exceeds manufacturer projections, reinforcing the need for standardised reporting criteria.
- Safety and performance of INGEVITYTM+ lead for LBBAP:3 An analysis by Santoro et al. builds on earlier evidence, further supporting the safety and reliability of the INGEVITY+ use in LBBAP implantation.
- Enhanced Detection Algorithms in ICMs: Richards M. et al.4 Algorithm refinement can improve the diagnostic yield of insertable cardiac monitoring by reducing false-positive detections while maintaining sensitivity.
Gain deeper insights by downloading the full newsletter
